Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H25FN4O2 |
Molecular Weight | 348.4151 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@H](NC(=O)C1=NN(CCCCCF)C2=CC=CC=C12)C(N)=O
InChI
InChIKey=WCBYXIBEPFZUBG-HNNXBMFYSA-N
InChI=1S/C18H25FN4O2/c1-12(2)15(17(20)24)21-18(25)16-13-8-4-5-9-14(13)23(22-16)11-7-3-6-10-19/h4-5,8-9,12,15H,3,6-7,10-11H2,1-2H3,(H2,20,24)(H,21,25)/t15-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26134475Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27773389 | http://www.google.ch/patents/WO2009106980A2 | https://www.ncbi.nlm.nih.gov/pubmed/25721194
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26134475
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27773389 | http://www.google.ch/patents/WO2009106980A2 | https://www.ncbi.nlm.nih.gov/pubmed/25721194
N-((1S)-1-(Aminocarbonyl)-2-methylpropyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-AB-PINACA) is an indazole-based synthetic cannabinoid developed by Pfizer in 2009 as an analgesic medication. In January 2015, AB-PINACA became a controlled substance in the USA and 5F-ABPINACA will be prohibited based on the analog law. 5F-AB-PINACA has been sold online as a designer drug.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL218 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26134475 |
9.32 null [pEC50] | ||
Target ID: CHEMBL253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26134475 |
8.59 null [pEC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://www.google.ch/patents/WO2009106980A2 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26134475
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1 or human CB2 were used for activity evaluation. Prior to the assay, cells were loaded with 90 μL/well of the dye solution without removal of the L-15, giving an initial assay volume of 180 μL/well. Plates were then incubated at 37 °C at ambient CO2 for 45 min. Fluorescence was measured using a FlexStation 3 (Molecular Devices) microplate reader with cells excited at a wavelength of 530 nm and emission measured at 565 nm. Baseline readings were taken every 2 s for at least 2 min, at which time either drug (5F-AB-PINACA) or vehicle was added in a volume of 20 μL. The background fluorescence of cells without dye or dye without cells was negligible. Changes in fluorescence were expressed as a percentage of baseline fluorescence after subtraction of the changes produced by vehicle addition, which was less than 2% for drugs dissolved in assay buffer or DMSO.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
7025
Created by
admin on Sat Dec 16 10:16:45 GMT 2023 , Edited by admin on Sat Dec 16 10:16:45 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-5F-AB-PINACA
Created by
admin on Sat Dec 16 10:16:45 GMT 2023 , Edited by admin on Sat Dec 16 10:16:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5F-AB-PINACA
Created by
admin on Sat Dec 16 10:16:45 GMT 2023 , Edited by admin on Sat Dec 16 10:16:45 GMT 2023
|
PRIMARY | |||
|
3L83B2298V
Created by
admin on Sat Dec 16 10:16:45 GMT 2023 , Edited by admin on Sat Dec 16 10:16:45 GMT 2023
|
PRIMARY | |||
|
DTXSID40100997
Created by
admin on Sat Dec 16 10:16:45 GMT 2023 , Edited by admin on Sat Dec 16 10:16:45 GMT 2023
|
PRIMARY | |||
|
1800101-60-3
Created by
admin on Sat Dec 16 10:16:45 GMT 2023 , Edited by admin on Sat Dec 16 10:16:45 GMT 2023
|
PRIMARY | |||
|
91936927
Created by
admin on Sat Dec 16 10:16:45 GMT 2023 , Edited by admin on Sat Dec 16 10:16:45 GMT 2023
|
PRIMARY |
ACTIVE MOIETY